Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients

Bibliographic Details
Main Authors:	Liu, Lin L., Li, Fei, Pao, William, Michor, Franziska
Format:	Online
Language:	English
Published:	Public Library of Science 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633116/

Similar Items

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
by: Schöttle, Jakob, et al.
Published: (2015)

Erlotinib ‘dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
by: Mita, A C, et al.
Published: (2011)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
by: Nguyen, Kim-Son H, et al.
Published: (2012)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
by: Karachaliou, Niki, et al.
Published: (2015)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
by: Zwitter, Matjaz, et al.
Published: (2016)

Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
by: ISHII, HIDENOBU, et al.
Published: (2014)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
by: Pao, William, et al.
Published: (2005)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
by: Tseng, Jeng-Sen, et al.
Published: (2014)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
by: Nakade, Junya, et al.
Published: (2014)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
by: Wang, Debby D., et al.
Published: (2015)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
by: Azuma, Koichi, et al.
Published: (2016)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
by: Gong, Yixuan, et al.
Published: (2007)

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
by: PETTY, W. JEFFREY, et al.
Published: (2013)

Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
by: Bahce, Idris, et al.
Published: (2016)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
by: Gonçalves, Ivone, et al.
Published: (2013)

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
by: Togashi, Yosuke, et al.
Published: (2011)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
by: Pao, William, et al.
Published: (2005)

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib
by: Mehmet Artaç, et al.
Published: (2018-08-01)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
by: Hung, Ming-Szu, et al.
Published: (2016)

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
by: Polychronidou, Genovefa, et al.
Published: (2013)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
by: Baty, Florent, et al.
Published: (2013)

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer
by: Li, Hongde, et al.
Published: (2016)

Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non–Small Cell Lung Cancer Cells1
by: Saygideğer-Kont, Yasemin, et al.
Published: (2016)

Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States
by: Enewold, Lindsey, et al.
Published: (2016)

Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
by: Sakai, Asao, et al.
Published: (2013)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
by: Liang, Wenhua, et al.
Published: (2014)

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
by: Greve, Gabriele, et al.
Published: (2015)

Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib
by: Takeda, Masayuki, et al.
Published: (2014)

Colchicine in acute gouty arthritis: the optimum dose?
by: Varughese, George I, et al.
Published: (2006)

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer
by: Krzakowski, M., et al.
Published: (2013)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
by: Nghiemphu, Phioanh Leia, et al.
Published: (2012)

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability
by: Iwami, Shingo, et al.
Published: (2012)

EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, Lichun, et al.
Published: (2015)

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
by: Goss, Glenwood D., et al.
Published: (2016)

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
by: Hirano, Toshiyuki, et al.
Published: (2015)

EGFR Mutations and Lung Cancer
Published: (2005)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
by: Jabbari, Siavash, et al.
Published: (2011)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
by: In Ae Kim, et al.
Published: (2018-07-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan, Ying, et al.
Published: (2012)